CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CytomX Therapeutics, Inc.

CytomX Therapeutics is a biopharmaceutical company that researches and develops therapies to combat cancer by using the disease's own mechanisms against itself.

CytomX Therapeutics

CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. 

Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. 

CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected.

We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population.

CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category.

CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.

Canaan Partners

Third Rock Ventures

Casdin Capital

Wellington Management

Perceptive Advisors

Redmile Group

Cormorant Asset Management

Deerfield

Tekla Capital Management

Venrock

Today we announced second quarter 2024 financial results, including progress related to our clinical-stage PROBODY® therapeutic programs. To learn more, read our press release and join our conference call and webcast at 5pm ET/2pm PT. https://lnkd.in/evS2MHHC

Happy National Intern Day! At CytomX, CREATIVITY is more than just a value—it's at the heart of everything we do. As we celebrate National Intern Day, we applaud our interns for embodying this core value, infusing their work in science with fresh perspectives and innovative thinking. They are the future of scientific discovery, paving the way for the next generation of leaders. Here's to the next generation of leaders shaping the future at CytomX!

Celebrating International Women's History Month at CytomX! As a culture that embraces diversity, we proudly honor the invaluable contributions of women in STEM. With over half of our organization being women, we recognize their significant impact and dedication. At CytomX, one of our values is COMMITMENT, and we are dedicated to our patients, teammates, and fostering a diverse and inclusive environment where everyone thrives. Here's to the inspiring women shaping the future of science and making significant impacts every day!

Happy Lunar New Year! This year marks the beginning of the Wood Dragon, symbolizing creativity and adaptability. At CytomX, we embrace CREATIVITY as one of our core values, as we believe that curiosity and innovation have the power to change lives! To celebrate, we hosted a special Lunar New Year Happy Hour, where we toasted the year ahead and honored the spirit of innovation that defines our work. Wishing everyone a prosperous and joyful year ahead! 🐲 🎊

At CytomX, our mission is to transform the lives of cancer patients with safer, more effective therapies through the development of novel conditionally activated biologics. Watch our CEO Sean McCarthy's recent conversation with
Precision AQ to learn more!

Today at 2pm ET, our chief executive officer and chairman Sean McCarthy will participate in a fireside chat at the H.C. Wainwright & Co., LLC 2nd Annual Immune Cell Engager Virtual Conference. Tune into the webcast to listen live or hear the replay: https://lnkd.in/e8FurEhJ

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	888K -	5.08M 471.73%	7.71M 51.90%	15.04M 95.06%	71.62M 376.12%	59.50M 16.92%	57.49M 3.38%	100.36M 74.58%	69.57M 30.68%	53.16M 23.59%	101.21M 90.38%
cost of revenue											2.17M -
gross profit	888K -	5.08M 471.73%	7.71M 51.90%	15.04M 95.06%	71.62M 376.12%	59.50M 16.92%	57.49M 3.38%	100.36M 74.58%	69.57M 30.68%	53.16M 23.59%	99.04M 86.29%
selling and marketing expenses											-146K -
general and administrative expenses	4.95M -	6.54M 32.01%	12.56M 92.02%	19.87M 58.26%	25.61M 28.84%	33.51M 30.87%	36.77M 9.71%	36.03M 2.00%	39.16M 8.68%	42.85M 9.42%	30.02M 29.94%
selling general and administrative expenses	4.95M -	6.54M 32.01%	12.56M 92.02%	19.87M 58.26%	25.61M 28.84%	33.51M 30.87%	36.77M 9.71%	36.03M 2.00%	39.16M 8.68%	42.85M 9.42%	29.87M 30.29%
research and development expenses	10.89M -	28.30M 159.89%	28.36M 0.19%	54.76M 93.09%	92.28M 68.53%	103.87M 12.56%	131.62M 26.72%	112.94M 14.19%	114.19M 1.11%	111.65M 2.23%	75.65M 32.24%
other expenses	71K -	-55K 177.46%	-1.74M 3,070.91%	-69K 96.04%	-27K 60.87%	-68K 151.85%	-135K 98.53%	-27K 80%	-83K 207.41%	340K 509.64%	-30K 108.82%
cost and expenses	15.84M -	34.84M 119.91%	40.91M 17.43%	74.63M 82.40%	117.88M 57.96%	137.38M 16.54%	168.38M 22.57%	148.97M 11.53%	153.35M 2.94%	154.50M 0.75%	107.70M 30.29%
operating expenses	15.84M -	34.84M 119.91%	40.91M 17.43%	74.63M 82.40%	117.88M 57.96%	137.38M 16.54%	168.38M 22.57%	148.97M 11.53%	153.35M 2.94%	154.50M 0.75%	105.52M 31.70%
interest expense	254K -	487K 91.73%	1.73M 255.65%	1.69M 2.48%						-2.02M -
ebitda	-14.22M -	-29.03M 104.09%	-32.43M 11.70%	-55.50M 71.15%	-44.61M 19.61%	-75.99M 70.33%	-110.89M 45.93%	-46.03M 58.49%	-83.78M 82.01%	-101.33M 20.95%	-4.31M 95.75%
operating income	-14.96M -	-29.77M 99.02%	-33.20M 11.55%	-59.59M 79.46%	-46.26M 22.37%	-77.87M 68.34%	-110.89M 42.40%	-48.60M 56.17%	-83.78M 72.37%	-101.33M 20.95%	-6.48M 93.60%
depreciation and amortization	655K -	783K 19.54%	1.21M 54.02%	1.73M 43.70%	1.65M 5.08%	1.88M 14.53%	2.60M 38.27%	2.57M 1.23%	2.71M 5.17%	2.44M 9.72%	2.17M 10.97%
total other income expenses net	71K -	-55K 177.46%	-1.74M 3,070.91%	-69K 96.04%	-27K 60.87%	-68K 151.85%	8.23M 12,202.94%	1.81M 78.02%	172K 90.49%	2.02M 1,073.26%	9.81M 385.98%
income before tax	-15.13M -	-30.30M 100.22%	-35.36M 16.71%	-58.92M 66.61%	-43.61M 25.98%	-70.30M 61.20%	-102.67M 46.04%	-46.80M 54.42%	-83.61M 78.67%	-99.32M 18.79%	3.32M 103.35%
income tax expense	10K -	10K 0%	10K 0%	-19K 290%	-513K 2,600%	14.30M 2,888.11%	-427K 102.99%	-13.91M 3,157.85%	-2.96M 78.71%	-2.02M 31.85%	3.89M 292.86%
net income	-15.14M -	-30.31M 100.16%	-35.37M 16.71%	-58.90M 66.51%	-43.10M 26.83%	-84.60M 96.30%	-102.24M 20.84%	-32.88M 67.83%	-80.65M 145.24%	-97.30M 20.65%	-569K 99.42%
weighted average shs out	34.92M -	34.92M 0%	8.60M 75.39%	36.23M 321.57%	37.17M 2.57%	41.66M 12.10%	45.34M 8.81%	46.15M 1.79%	64.15M 39.01%	65.74M 2.48%	73.81M 12.27%
weighted average shs out dil	34.92M -	34.92M 0%	8.60M 75.39%	36.23M 321.57%	37.17M 2.57%	41.66M 12.10%	45.34M 8.81%	46.15M 1.79%	64.15M 39.01%	65.74M 2.48%	73.81M 12.27%
eps	-0.43 -	-0.87 102.33%	-4.12 373.56%	-1.63 60.44%	-1.16 28.83%	-2.03 75%	-2.26 11.33%	-0.71 68.58%	-1.26 77.46%	-1.48 17.46%	-0.01 99.48%
epsdiluted	-0.43 -	-0.87 102.33%	-4.12 373.56%	-1.63 60.44%	-1.16 28.83%	-2.03 75%	-2.26 11.33%	-0.71 68.58%	-1.26 77.46%	-1.48 17.46%	-0.01 99.48%

COM:CYTOMX

CytomX Therapeutics

Last Close

0.87

22/11 21:00

Market Cap

102.07M

Beta: -

Volume Today

1.23K

Avg: -

Preview